Relationship Between Platelet to Lymphocyte Ratio and Stable Coronary Artery Disease: Meta-Analysis of Observational

Zhiqiang Qiu1, Yu Jiang2, Xinghua Jiang2

  • 1Department of Orthopedics, 47861Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.

Angiology
|July 29, 2020
PubMed

Insights

The platelet to lymphocyte ratio (PLR) is elevated in patients with stable coronary artery disease (CAD). This marker may help predict the severity of CAD, including stenosis, collateral circulation, and coronary slow flow.

Area of Science:

  • Cardiology
  • Hematology
  • Biomarkers

Background:

  • Recent research suggests a link between the platelet to lymphocyte ratio (PLR) and acute coronary syndromes.
  • The association between PLR and stable coronary artery disease (CAD) requires further investigation.

Purpose of the Study:

  • To systematically investigate the relationship between PLR and stable CAD.
  • To evaluate PLR's potential as a predictive marker for CAD severity.

Main Methods:

  • A comprehensive systematic search of major electronic databases (Cochrane, PubMed, Elsevier, Medline, Embase).
  • Meta-analysis of 14 studies including 4,871 participants.
  • Analysis of PLR in relation to CAD presence, Gensini score, coronary collateral circulation (CCC), and coronary slow flow (CSF).

Main Results:

  • Elevated PLR was significantly associated with the presence of stable CAD (P = .002).
  • Higher PLR levels correlated with increased atherosclerosis severity (P < .001) and severe stenosis.
  • PLR was lower in patients with good CCC (P < .001) and higher in those with CSF (P = .01).

Conclusions:

  • An elevated PLR is linked to stable CAD.
  • PLR may serve as a valuable predictive biomarker for CAD severity, including stenosis, collateral circulation, and CSF.
  • Further research is warranted to fully elucidate the role of PLR in stable CAD.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
513
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
261
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
123
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
748
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
928
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
163